Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Clearside Biomedical, Inc. (CLSD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., August 14, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The last several months have been very productive for Clearside with the initiation..."
05/11/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 11, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We have delivered a productive start to 2023 as we continue exec..."
03/09/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in Retinal Specialists Trained in Suprachoroidal Space Injection Procedure Using FDA-Approved XIPERE® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 9, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the fourth ..."
11/09/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "Three Months Ended December 31, Year Ended December 31, 2021 2020 2021 2020 License and other revenue $ 25,687 $ 11 $ 29,575 $ 7,894 Operating expenses: Research and development 3,840 4,472 18,537 15,073 General and administrative 3,140 2,649 11,665 10,756 Total operating expenses 6,980 7,121 30,202 25,829 Income from operations 18,707 Other income 2 ̶— 1,003 — Other expense — — Net income $ 18,709 $ $ 376 $ Net income per share of common stock — basic and diluted $ 0.31 $ $ 0.01 $ Weighted average shares outstanding — basic 59,669,759 49,048,402 58,491,986 46,506,540 Weighted average shares outstanding — diluted 61,182,414 49,048,402 59,906,602 46,506,540 Balance Sheet Data December 31, December 31, 2021 2020 Cash and cash equivalents $ 30,436 $ 17,287 Accounts receivable 10,000 — ..."
11/10/2021 8-K Quarterly results
Docs: "Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 License and other revenue $ 3,074 $ 3,432 $ 3,888 $ 7,883 Operating expenses: Research and development 5,147 3,490 14,697 10,601 General and administrative 2,816 2,374 8,525 8,107 Total operating expenses 7,963 5,864 23,222 18,708 Loss from operations Other income 2 ̶— 1,001 — Other expense — — Net loss $ $ $ $ Net loss per share of common stock — basic and diluted $ $ $ $ Weighted average shares outstanding — basic and diluted 59,474,346 46,976,649 58,095,080 45,653,068 Balance Sheet Data September 30, December 31, 2021 2020 Cash and cash equivalents $ 25,217 $ 17,287 Total assets 27,378 19,322 Deferred revenue 5,000 5,000 Long-term debt — 991 Total liabilities 9,530 10,559 Total stockholders’ equ..."
08/10/2021 8-K Quarterly results
Docs: "Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 License and other revenue $ 780 $ 354 $ 814 $ 4,451 Operating expenses: Research and development 4,060 3,300 9,550 7,111 General and administrative 2,816 2,611 5,709 5,733 Total operating expenses 6,876 5,911 15,259 12,844 Loss from operations Other income 1 — 999 — Other expense — — Net loss $ $ $ $ Net loss per share of common stock — basic and diluted $ $ $ $ Weighted average shares outstanding — basic and diluted 57,745,465 45,214,500 57,394,017 44,984,005 Balance Sheet Data June 30, December 31, 2021 2020 Cash and cash equivalents $ 26,414 $ 17,287 Total assets 28,592 19,322 Deferred revenue 5,000 5,000 Long-term debt — 991 Total liabilities 9,254 10,559 Total stockholders’ equity 19,338 8,763 Source: Clearsid..."
05/17/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "CLEARSIDE BIOMEDICAL, INC."
08/10/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Clearside Biomedical Announces Third Quarter 2019 Financial Results and Provides Corporate Update – Recent Partnerships Support the Broad Applicability of Suprachoroidal Space Injection Platform to Potentially Treat Multiple Ocular Diseases –"
08/07/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Statement of Operations Data Three Months Ended March 31, 2019 2018"
03/12/2019 8-K Quarterly results
Docs: "Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update - Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -"
11/08/2018 8-K Quarterly results
Docs: "Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update"
08/08/2018 8-K Quarterly results
Docs: "Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update"
05/09/2018 8-K Quarterly results
Docs: "Statements of Operations Data Three Months Ended March 31, 2018 2017"
03/14/2018 8-K Quarterly results
Docs: "Statements of Operations Data Three Months Ended December 31, Year Ended December 31, 2017 2016 2017 2016"
11/08/2017 8-K Quarterly results
Docs: "Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update"
08/09/2017 8-K Quarterly results
Docs: "Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update"
05/10/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/11/2016 8-K Quarterly results
Docs: "Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results Alpharetta, GA — Clearside Biomedical, Inc. , a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported a corporate update and financial results for the quarter ended June 30, 2016. “Completing our IPO in June provided the financial resources to continue our clinical efforts in administering drug therapies through the suprachoroidal space for the treatment of patients suffering from sight-threatening diseases,” said Daniel H. White, Chief Executive Officer and President. “The team at Clearside achieved some very important milestones in the second quarter of 2016 with the completion of our Phase 2 trial using Zuprata™ to treat macular ..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy